BLBAUPOST GROUP LLC/MA
Institutional investor · Portfolio as of Q4 2018
Top Holdings37 positions
| 51.3M | $2.5B | 21.4% | — | — | 1 qtr | First report 0 | |
CHENIERE ENERGY INC | 14.2M | $840.3M | 7.3% | $56.31 | 0.00% | 1 qtr | First report 0 |
| 17M | $814.2M | 7.1% | $10.64 | +200.85% | 1 qtr | First report 0 | |
VIASAT INC | 13.7M | $809.5M | 7.0% | $58.03 | 0.00% | 1 qtr | First report 0 |
QORVO INC | 10.7M | $648.7M | 5.6% | $60.79 | 0.00% | 1 qtr | First report 0 |
ALLERGAN PLC | 4.8M | $635.6M | 5.5% | — | — | 1 qtr | First report 0 |
LIBERTY GLOBAL PLC | 29.7M | $613.9M | 5.3% | — | — | 1 qtr | First report 0 |
PIONEER NAT RES CO | 4.5M | $591.8M | 5.1% | — | — | 1 qtr | First report 0 |
EBAY INC. | 21M | $589.5M | 5.1% | $25.13 | 0.00% | 1 qtr | First report 0 |
PG&E CORP | 15.5M | $367.5M | 3.2% | $23.62 | 0.00% | 1 qtr | First report 0 |
| 300M | $364.1M | 3.2% | — | — | — | First report 0 | |
SYNCHRONY FINANCIAL | 14.6M | $341.4M | 3.0% | $19.63 | 0.00% | 1 qtr | First report 0 |
ANTERO RESOURCES CORP | 28.6M | $268.4M | 2.3% | $9.21 | 0.00% | 1 qtr | First report 0 |
THERAVANCE BIOPHARMA INC | 9.3M | $238.2M | 2.1% | $23.43 | 0.00% | 1 qtr | First report 0 |
COLONY CAP INC NEW | 49.7M | $232.5M | 2.0% | — | — | 1 qtr | First report 0 |
ATARA BIOTHERAPEUTICS INC | 6.3M | $217.3M | 1.9% | — | — | — | First report 0 |
MCKESSON CORP | 1.7M | $190M | 1.6% | $104.44 | 0.00% | 1 qtr | First report 0 |
UNIVAR SOLUTIONS INC | 9.5M | $168.5M | 1.5% | — | — | 1 qtr | First report 0 |
CENCORA INC | 2M | $149.9M | 1.3% | $57.70 | 0.00% | 1 qtr | First report 0 |
AKEBIA THERAPEUTICS INC | 24.5M | $135.3M | 1.2% | $5.39 | 0.00% | 1 qtr | First report 0 |
BAUPOST GROUP LLC/MA manages $11.5B across 37 positions as of Q4 2018. Top holdings: NWS/A (21.4%), LNG (7.3%), NWS (7.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 4.5/5.0.
First quarter we have for this fund: 37 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $11.5B across 37 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR